Publicly traded, late-stage drug development company Aeterna Zentaris, based in Quebec, has appointed Michael Meyers to its board. Meyers cofounded Arcoda Capital Management of New York, which manages long-short funds that invest primarily in publicly traded healthcare companies.
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), a late-stage drug development company specialized in oncology and endocrinology, is pleased to announce the appointment of Michael Meyers, MPH, to its Board of Directors.
Mr. Meyers is a co-founding member, Chief Executive Officer and Chief Investment Officer of Arcoda Capital Management LP, managing the Arcoda Global Healthcare Funds, long-short funds investing primarily in publicly traded equity securities of healthcare companies across a range of healthcare sub-sectors. Prior to founding Arcoda in 2007, Mr. Meyers was a Partner and Portfolio Manager of GoldenTree Asset Management LP. Between 2002 and 2006, he was a founding Managing Partner, Portfolio Manager and Sector Head of Healthcare of a long-short money management firm in New York.
Between 2000 and 2003, Mr. Meyers was a Managing Director, Partner and Director of a life sciences venture capital firm located in New York and Zurich, Switzerland. Between 1997 and 2000, he was Director, Biotechnology and Pharmaceutical Investment Banking at Merrill Lynch & Co. Between 1993 and 1997, Mr. Meyers was Vice President, Health Care Investment Banking at Cowen & Company. He held earlier positions at St. Barnabas Hospital system, and Hambrecht & Quist in New York. Mr. Meyers holds a Masters in Public Health, in Health Policy and Management, from Columbia University and an A.B. in Biology from Brandeis University.
Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, “Michael Meyers brings a tremendous amount of experience to Aeterna Zentaris, and we are very pleased to have him serve on our Board. His track record of investment management in the life sciences sector is extraordinary, and will be of great assistance to us as we focus on bringing our late-stage oncology compounds closer to market.”
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.